Comments
Moderna, an American biotechnology company, is in talks with numerous countries for supply deals for its much-awaited Covid-19 vaccine, the company said in an official statement.
The firm, which discovers and develops vaccines for various infections and diseases, said it would charge between $32 to $37 per dose, which it sees as cheaper “pandemic pricing”.
The company said it has already received $400 million in deposits from multiple governments for its potential vaccine against the virus.
Moderna’s vaccine candidate named mRNA-1273 will hit the markets as early as October, after finishing phase three of trials that have enrolled 30,000 people.
Moderna CEO Stephane Bancel said in the statement: “As we pivot to a commercial-stage company, we recognise the need for responsible pricing in the face of the pandemic.”
The company has received $1 billion from the US government in order to accelerate the development of the vaccine.
Moderna’s vaccine has RNA, which is a genetic material that causes cells to produce spike protein for coronavirus and induces an immune response from the body.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.